Greenwich LifeSciences, Inc. (NASDAQ:GLSI) Sees Significant Growth in Short Interest

Greenwich LifeSciences, Inc. (NASDAQ:GLSI) was the recipient of a significant increase in short interest during the month of December. As of December 15th, there was short interest totalling 530,200 shares, an increase of 8.1% from the November 30th total of 490,400 shares. Based on an average daily trading volume, of 28,200 shares, the short-interest ratio is presently 18.8 days. Currently, 9.0% of the company’s shares are sold short.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of GLSI. Garden State Investment Advisory Services LLC acquired a new stake in Greenwich LifeSciences in the third quarter worth $253,000. Bank of New York Mellon Corp acquired a new stake in Greenwich LifeSciences during the 2nd quarter worth $264,000. Rhumbline Advisers bought a new position in Greenwich LifeSciences during the second quarter worth about $117,000. Barclays PLC grew its stake in Greenwich LifeSciences by 323.3% in the third quarter. Barclays PLC now owns 8,560 shares of the company’s stock valued at $123,000 after acquiring an additional 6,538 shares during the period. Finally, Geode Capital Management LLC grew its stake in Greenwich LifeSciences by 4.6% in the third quarter. Geode Capital Management LLC now owns 133,550 shares of the company’s stock valued at $1,919,000 after acquiring an additional 5,861 shares during the period. Institutional investors and hedge funds own 4.16% of the company’s stock.

Greenwich LifeSciences Trading Up 2.9 %

Shares of GLSI stock traded up $0.32 on Wednesday, reaching $11.23. The company had a trading volume of 42,190 shares, compared to its average volume of 39,041. The stock has a market cap of $147.62 million, a PE ratio of -14.04 and a beta of 1.61. The company has a 50-day moving average of $13.29 and a 200-day moving average of $14.27. Greenwich LifeSciences has a 12 month low of $8.00 and a 12 month high of $21.44.

About Greenwich LifeSciences

Greenwich LifeSciences, Inc, a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.